Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma.
Smith MR, Jegede O, Martin P, Till B, Parekh S, Yang DT, Hsi ED, Witzig TE, Dave SS, Scott DW, Hanson CA, Kostakoglu L, Abdel Samad NN, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum K, Romer M, Inwards DJ, Lerner R, Wagner L, Little RF, Friedberg JW, Leonard JP, Kahl BS. Smith MR, et al. Among authors: casulo c. Blood. 2024 May 31:blood.2024023962. doi: 10.1182/blood.2024023962. Online ahead of print. Blood. 2024. PMID: 38820500
Defining Primary Refractory Large B-cell Lymphoma.
Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl BS, Martin P, Cohen JB, Casulo C, Lossos IS, Farooq U, Ayyappan S, Reicks TW, Habermann TM, Witzig TE, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski GS. Bock AM, et al. Among authors: casulo c. Blood Adv. 2024 Apr 26:bloodadvances.2024012760. doi: 10.1182/bloodadvances.2024012760. Online ahead of print. Blood Adv. 2024. PMID: 38669353
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson PG, Hopkins D, Ng A, Casulo C, Baron J, Roberts KB, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin LJ, Henry M, Smith CM, Halperin D, Brady J, Brennan B, Senchenko MA, Reeves M, Hoppe BS, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes EA, Lee D, Doo NW, Barraclough A, Cheah CY, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer MJ, Eichenauer DA, Hoppe RT; GLOW Consortium. Binkley MS, et al. Among authors: casulo c. J Clin Oncol. 2024 Mar 26:JCO2301655. doi: 10.1200/JCO.23.01655. Online ahead of print. J Clin Oncol. 2024. PMID: 38531001
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. Cerhan JR, et al. Among authors: casulo c. Am J Hematol. 2024 Mar;99(3):408-421. doi: 10.1002/ajh.27202. Epub 2024 Jan 13. Am J Hematol. 2024. PMID: 38217361
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Maurer MJ, Casulo C, Larson MC, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan JR, Link BK, Flowers CR. Maurer MJ, et al. Among authors: casulo c. Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283737. Online ahead of print. Haematologica. 2023. PMID: 38031804 Free article.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA. Neelapu SS, et al. Among authors: casulo c. Blood. 2024 Feb 8;143(6):496-506. doi: 10.1182/blood.2023021243. Blood. 2024. PMID: 37879047 Free PMC article.
Personalised therapy in follicular lymphoma - is the dial turning?
Linton KM, Specht L, Pavlovsky A, Thompson CA, Kimby E, de Jong D, Nastoupil LJ, Cottereau AS, Casulo C, Sarkozy C, Okosun J. Linton KM, et al. Among authors: casulo c. Hematol Oncol. 2023 Jul 22. doi: 10.1002/hon.3205. Online ahead of print. Hematol Oncol. 2023. PMID: 37482955 Review.
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM. Wallace DS, et al. Among authors: casulo c. Leuk Lymphoma. 2023 Sep;64(9):1579-1582. doi: 10.1080/10428194.2023.2223743. Epub 2023 Jun 21. Leuk Lymphoma. 2023. PMID: 37341984 Clinical Trial. No abstract available.
83 results